



## (51) International Patent Classification:

*C07D 471/04* (2006.01) *A61P 3/10* (2006.01)  
*A61K 31/519* (2006.01) *A61P 3/04* (2006.01)

## (21) International Application Number:

PCT/KR2011/008186

## (22) International Filing Date:

31 October 2011 (31.10.2011)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

10-2010-0107868 1 November 2010 (01.11.2010) KR

(71) Applicant (for all designated States except US): **LG LIFE SCIENCES LTD.** [KR/KR]; LG Gwanghwamun Bldg., 92, Sinmunno 2-ga, Jongno-gu, Seoul 110-062 (KR).

## (72) Inventors; and

(75) Inventors/Applicants (for US only): **PARK, Ki Sook** [KR/KR]; R&D Park, LG Life Sciences Ltd., 104-1, Moongi-dong, Yuseong-gu, Daejeon 305-380 (KR). **YUN, Jung Min** [KR/KR]; R&D Park, LG Life Sciences Ltd., 104-1, Moongi-dong, Yuseong-gu, Daejeon 305-380 (KR). **KIM, Bong Chan** [KR/KR]; R&D Park, LG Life Sciences Ltd., 104-1, Moongi-dong, Yuseong-gu, Daejeon 305-380 (KR). **KIM, Kyu Young** [KR/KR]; R&D Park, LG Life

Sciences Ltd., 104-1, Moongi-dong, Yuseong-gu, Daejeon 305-380 (KR). **LEE, Ji Hye** [KR/KR]; R&D Park, LG Life Sciences Ltd., 104-1, Moongi-dong, Yuseong-gu, Daejeon 305-380 (KR).

(74) Agent: **CHOL, Kyu Pal**; Halla Classic Building 4F., 824-11, Yeoksam-dong, Kangnam-gu, Seoul 135-080 (KR).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: HYDRATE OF 1-{(2S)-2-AMINO-4-[2,4-BIS(TRIFLUOROMETHYL)-5,8-DI-HYDROPYRIDO[3,4-D]PYRIMIDIN-7(6H)-YL]-4-OXOBUTYL}-5,5-DIFLUORO-PIPERIDIN-2-ONE TARTRATE

[Fig. 1]



(57) Abstract: The present invention relates to 1.5 hydrate of 1-{(2S)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl]-4-oxobutyl}-5,5-difluoropiperidin-2-one tartrate, a process for preparing the same, and a pharmaceutical composition for inhibiting DPP-IV, which comprises said compound as the active component.

**Published:****(88) Date of publication of the international search report:**

28 June 2012

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*